Furthermore, our results demonstrated that up-regulated HSP90 was also a significant prognostic factor in HER2-/ER+ breast cancers, suggesting a broad application of HSP90 targeted therapies in the 80% of breast cancers that do not over-express HER2. The gene discussed is ERBB2; the disease is breast cancer.